Vizz is a drug owned by Lenz Therapeutics Inc. It is protected by 4 US drug patents filed in 2025 out of which none have expired yet. Vizz's patents will be open to challenges from 31 July, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 08, 2039. Details of Vizz's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12128036 | NA |
Oct, 2039
(14 years from now) | Active |
| US10052313 | NA |
Mar, 2034
(8 years from now) | Active |
| US9844537 | NA |
Mar, 2034
(8 years from now) | Active |
| US11179328 | NA |
Mar, 2034
(8 years from now) | Active |
FDA has granted several exclusivities to Vizz. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vizz, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vizz.
Exclusivity Information
Vizz holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Vizz's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
US patents provide insights into the exclusivity only within the United States, but Vizz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vizz's family patents as well as insights into ongoing legal events on those patents.
Vizz's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vizz's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 08, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vizz Generics:
There are no approved generic versions for Vizz as of now.
Alternative Brands for Vizz
There are several other brand drugs in the same treatment category as Vizz. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Orasis Pharms |
| |||
About Vizz
Vizz is a drug owned by Lenz Therapeutics Inc. Vizz uses Aceclidine Hydrochloride as an active ingredient. Vizz was launched by Lenz Therap in 2025.
Approval Date:
Vizz was approved by FDA for market use on 31 July, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Vizz is 31 July, 2025, its NCE-1 date is estimated to be 31 July, 2029.
Active Ingredient:
Vizz uses Aceclidine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Aceclidine Hydrochloride ingredient
Dosage:
Vizz is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1.44% BASE | SOLUTION/DROPS | Prescription | OPHTHALMIC |